MedPath

SMOK-study: selective serotonin reuptake inhibitor medication in pregnant women - effect on development of childre

Completed
Conditions
SSRI (selective serotonin reuptake inhibitor), pregnancy
Pregnancy and Childbirth
Antidepressant use in pregnancy
Registration Number
ISRCTN53506435
Lead Sponsor
niversity Medical Centre Groningen (UMCG) (The Netherlands)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
120
Inclusion Criteria

Newborn child exposed to an SSRI in utero

Exclusion Criteria

1. Newborn child exposed to a non-SSRI antidepressant in utero
2. Newborn child exposed to anti-epileptic drugs in utero

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. In the first week after birth and at three months post-term: quality of general movements<br>2. At the age of 2 years and 6 years: motor and cognitive development
Secondary Outcome Measures
NameTimeMethod
o secondary outcome measures
© Copyright 2025. All Rights Reserved by MedPath